Evidence map›Paper›PMID 28697764›Full record

ArticleMolecular cancer2017

Long non-coding RNA linc00673 regulated non-small cell lung cancer proliferation, migration, invasion and epithelial mesenchymal transition by sponging miR-150-5p.

Wei Lu, Honghe Zhang, Yuequn Niu, Yongfeng Wu, Wenjie Sun, Hongyi Li, Jianlu Kong, Kefeng Ding, Han-Ming Shen, Han Wu and 2 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Molecular cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 192 papers.

0numbers the graph read from it
0cells of the map it votes in
192citing papers in PubMed
11.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

192 citing papers in PubMed, 308 citations in OpenAlex.

  1. miR‑205: A dual regulator of angiogenesis in health and disease (Review).International journal of molecular medicine · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

132 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Wei LuDepartment of Toxicology, Zhejiang University School of Public Health, 866 Yuhangtang Road, Hangzhou, People's Republic of China.
Honghe ZhangDepartment of Pathology, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
Yuequn NiuDepartment of Toxicology, Zhejiang University School of Public Health, 866 Yuhangtang Road, Hangzhou, People's Republic of China.
Yongfeng WuDepartment of Toxicology, Zhejiang University School of Public Health, 866 Yuhangtang Road, Hangzhou, People's Republic of China.
Wenjie SunDepartment of Pathology, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
Hongyi LiDepartment of Toxicology, Zhejiang University School of Public Health, 866 Yuhangtang Road, Hangzhou, People's Republic of China.
Jianlu KongDepartment of Pathology, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
Kefeng DingDepartment of Surgical Oncology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
Han-Ming ShenDepartment of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Han WuDepartment of Ophthalmology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
Dajing XiaDepartment of Toxicology, Zhejiang University School of Public Health, 866 Yuhangtang Road, Hangzhou, People's Republic of China. dxia@zju.edu.cn.
Yihua WuDepartment of Toxicology, Zhejiang University School of Public Health, 866 Yuhangtang Road, Hangzhou, People's Republic of China. georgewuer@126.com.
Zhejiang University · CNSecond Affiliated Hospital of Zhejiang University · CNNational University of Singapore · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe function of a new long non-coding RNA linc00673 remains unclear. While identified as an oncogenic player in non-small cell lung cancer (NSCLC), linc00673 was found to be anti-oncogenic in pancreatic ductal adenocarcinoma (PDAC). However whether linc00673 regulated malignancy and epithelial mesenchymal transition (EMT) has not been characterized.

methodsCell proliferation was assessed using CCK-8 and EdU assays, and cell migration and invasion were assessed using scratch assays and transwell invasion assays. Epithelial mesenchymal transition was examined using western blot, qRT-PCR and immunofluorescence staining. Interaction between miRNA and linc00673 was determined using luciferase reporter assays. In vivo experiments were performed to assess tumor formation. In addition, the expression data of NSCLC specimens of TCGA and patient survival data were utilized to explore the prognostic significance of linc00673.

resultsIn the present study, we found high linc00673 expression was associated with poor prognosis of NSCLC patients. In vitro experiments showed linc00673 knockdown reversed TGF-β induced EMT, and miR-150-5p was predicted to target linc00673 through bioinformatics tools. Overexpression of miR-150-5p suppressed lin00673's expression while inhibition of miR-150-5p led to significant upregulation of lin00673, suggesting that linc00673 could be negatively regulated by miR-150-5p, which was further confirmed by the inverse correlation between linc00673 and miR-150-5p in NSCLC patients' specimen. Furthermore, we proved that miR-150-5p could directly target linc00673 through luciferase assay, so linc00673 could sponge miR-150-5p and modulate the expression of a key EMT regulator ZEB1 indirectly. In addition, miR-150-5p inhibition abrogated linc00673 silence mediated proliferation, migration, invasion and EMT suppressing effect. Moreover, the inhibition of linc00673 significantly attenuated the tumorigenesis ability of A549 cells in vivo.

conclusionsWe validated linc00673 as a novel oncogenic lncRNA and demonstrated the molecular mechanism by which it promotes NSCLC, which will advance our understanding of its clinical significance.

Indexed as

ApoptosisBase SequenceCarcinoma, Non-Small-Cell LungCell Line, TumorCell MovementCell ProliferationCell SurvivalEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticHumansLung NeoplasmsMicroRNAsModels, BiologicalNeoplasm InvasivenessRNA, Long NoncodingSurvival AnalysisMicroRNAsMIR150, humanRNA, Long NoncodingZEB1 protein, humanZinc Finger E-box-Binding Homeobox 1Competing endogenous RNAEpithelial mesenchymal transitionlinc00673miR-150-5pNon-small cell lung cancer

Identifiers

PMID28697764
PMCPMC5504775
OpenAlexW4232542801

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.